Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.


Çobanoğlu N., Özçelik U., Çakır E. , Şişmanlar E., Pekcan S., Cinel G., ...More

Pediatric pulmonology, vol.55, pp.2302-2306, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55
  • Publication Date: 2020
  • Doi Number: 10.1002/ppul.24854
  • Title of Journal : Pediatric pulmonology
  • Page Numbers: pp.2302-2306
  • Keywords: cystic fibrosis, modulator drugs, national registry, TEZACAFTOR-IVACAFTOR

Abstract

Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.